Abstract 1956
Background
Fatigue is the most common and distressing symptom of which castration resistant prostate cancer (CRPC) patients complain. The little evidence of fatigue prevalence, intensity and interference with daily activities in advanced prostate cancer that exists is mainly restricted to post-docetaxel setting with Abiraterone Acetate (AA). The VITAL study examines the prevalence and intensity of cancer-related fatigue (CRF) in CRPC.
Methods
cross-sectional study of CRPC patients including chemo-naïve metastatic (mCRPC) or high risk M0CRPC (PSADT ≤ 10mo) in routine clinical practice. Fatigue and Quality of Life (QoL) data were collected using validated patient self-reported questionnaires(BFI-SF and FACT-G/P). Fatigue correlation with both patient's and physiciańs perception was assessed.
Results
235 patients were recruited (Jan-Sept 2015). Median age: 75.1 (46.2-92.4), median PSA: 17.8 ng/ml (0-2000), metastatic disease: 68.5%, ECOG 0-1: 90.6%. There was a high prevalence of fatigue (M1:73.9%; M0: 74.3%), with 38.3% of the patients having moderate or severe fatigue. High concordance existed between fatigue physiciańs and patient's perception (Kappa index: 0.818). Cardiovascular and respiratory disorders were associated with an increase of fatigue in the multivariate analysis (OR: 4.7 and 3.6 respectively, p
Conclusions
Our data show a high prevalence and intensity of fatigue and impact in QoL in chemo-naïve CRPC patients. The study highlights the relevance of fatigue awareness and its management in CRPC patients. Table.
FACT-G total score | FACT-P total score | |||||
---|---|---|---|---|---|---|
FATIGUE | Mean | SD | N | Mean | SD | N |
Abscence | 88.0 | 13.3 | 60 | 127.7 | 16.9 | 60 |
Mildly | 79.3 | 12.9 | 84 | 110.1 | 16.3 | 84 |
Moderate | 71.5 | 14.7 | 64 | 110.8 | 19.3 | 64 |
Severe | 63.2 | 19.2 | 25 | 87.7 | 25.1 | 25 |
p-valor* | Clinical trial identificationLegal entity responsible for the studyJannsen-Cilag, Spain FundingJanssen-Cilag, Spain DisclosureAll authors have declared no conflicts of interest. Resources from the same session2354 - The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institutionPresenter: Seung Tae Kim Session: Poster Display Resources: Abstract 2594 - Neuroendocrine carcinomas of the colorectal origin - Polish experiencePresenter: Agnieszka Kolasińska-Ćwikła Session: Poster Display Resources: Abstract 2539 - Neuroendocrine neoplasms of the appendix including goblet cell carcinoidsPresenter: Agnieszka Kolasinska-Cwikla Session: Poster Display Resources: Abstract 1245 - Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendixPresenter: Amir Mehrvarz Sarshekeh Session: Poster Display Resources: Abstract 3902 - Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET)Presenter: Riccardo Marconcini Session: Poster Display Resources: Abstract 3882 - Differential clinical and pathological characteristics of hereditary neuroendocrine pancreatic tumours (NEPT)Presenter: Gema Marín Zafra Session: Poster Display Resources: Abstract 2296 - Natural course of thyroid cancer nodules compared with benign thyroid nodulesPresenter: Kyung-Jin Yun Session: Poster Display Resources: Abstract 4083 - Reassessment of proliferative activity at disease progression in neuroendocrine neoplasmsPresenter: Noemi Cicchese Session: Poster Display Resources: Abstract 3866 - 18F-FDG-PET to predict disease progression in advanced digestive neuroendocrine neoplasmsPresenter: Maria Rinzivillo Session: Poster Display Resources: Abstract 3651 - UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE studyPresenter: John Ramage Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|